Anti-Human Beta-Site APP Cleaving Enzyme 2 (NT) (BACE2)
Anti-Human Beta-Site APP Cleaving Enzyme 2 (NT) (BACE2) (B364-GRP)
Products
Description
Accumulation of the amyloid-β (αβ) plaque in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease. αβ peptide is generated by proteolytic cleavage of the β-amyloid protein precursor (APP) at β- and γ-sites by proteases. The long-sought β-secretase was recently identified by several groups independently and designated β-site APP cleaving enzyme (BACE) and aspartyl protease 2 (Asp2).1-4 A BACE homolog was recently cloned and designated BACE2, Asp1, DRAP (for Down region aspartic protease), and memapsin 1.4-9 BACE2 also cleaves APP at β-site and at a different site within αβ.8 BACE2 locates on chromosome 21q22.3, the so-called ‘Down critical region’, suggesting that BACE2 and αβ may also contribute to the pathogenesis of Down syndrome.6,7
Specifications
| Manufacturer Cat# | B364 |
|---|---|
| Concentration | 0.5 mg/ml |
| Formulation | This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative. |
| Target | BACE2 |
| Applications | IHC FFPE, WB |
| Storage | This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. |
| Protein | BACE2 |